Support for the development of this risk calculator was provided by Alberta Health Services (Cardiovascular Health and Stroke Strategic Clinical Network) and Merck Canada. ![]() Tsuyuki, BSc(Pharm), PharmD, MSc, FCSHP, FACC Charlotte A Jones, MD, PhD, FRCHP(C) Brenda R. While the authors have tested the tool and used it in the R圎ACH study, the authors take no responsibility for results or outcomes resulting from your use of it. This tool is provided for educational purposes and should not replace sound clinical judgment. General cardiovascular risk profile for use in primary care: The Framingham heart study. Heart 2013 99:866-872.ĭ’Agostino RB, Vasan RS, Pencina MJ et al. Development and validation of a prediction rule for recurrent vascular events based on a cohort study in patients with arterial disease: the SMART risk score. Clin Sci 2001 101: 671-9.ĭorresteijn JAN, Visseren FLJ, Wassink AMJ et al. ![]() risk assessment in diabetes mellitus : comparison of UKPDS risk engine with. included the following: Type 1 diabetes mellitus gestational. The UKPDS risk engine: a model for the risk of coronary heart disease in type 2 diabetes (UKPDS 56). Diabetes Control and Complications Trial Research Group The effect of. the UK Prospective Diabetes Study (UKPDS) risk engine, which is a T2DMspecific risk. Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR. ![]() 1 2 When this happens, the pancreas stops creating insulin. Effectiveness of Community Pharmacist Prescribing and Care on Cardiovascular Risk Reduction: Randomized Controlled R圎ACH Trial. When a person develops type 1 diabetes, the body’s immune system attacks the cells in the pancreas that makes insulin. Tsuyuki RT, Al Hamarneh YN, Jones CA, Hemmelgarn BR.
0 Comments
Leave a Reply. |